University Of Cologne

• A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R… Pending
  2024-513445-37-00 Phase III 4 countries DOXORUBICIN HYDROCHLORIDE; PIRTOBRUTINIB; RITUXIMAB
• Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending
  2024-517295-37-00 Phase III 1 country
• Antisense Oligonucleotide Eye Drops against IRS-1 to Optimize Pretransplant Lymphangio-regression Prior to High-Risk Keratoplasty (Olisens-P… Pending
  2025-522099-10-00 Phase II 1 country AGANIRSEN; DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.; OFLOXACIN
• OLISENS-ANIRIDIA Pending
  2025-522609-39-00 Phase II 1 country AGANIRSEN
• A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in… Pending
  2026-525640-14-00 Phase IV 1 country
• PREFer Recruiting
  2024-520138-31-00 Phase II 1 country PEMBROLIZUMAB
• STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease Recruiting
  2025-521276-59-00 Phase III 4 countries DAPAGLIFLOZIN
• A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting
  2023-506414-46-00 Phase III 3 countries
• Pembro-FLASH Recruiting
  2022-501458-13-01 Phase II 1 country BRENTUXIMAB VEDOTIN; PEMBROLIZUMAB
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting
  2023-510294-34-00 Phase III 14 countries OBINUTUZUMAB; VENETOCLAX
• Maintenance of durvalumab and olaparib after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive ext… Recruiting
  2024-512373-27-00 Phase II 1 country DURVALUMAB; OLAPARIB
• A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBI-TOR, PLUS… Recruiting
  2023-504653-12-00 Phase II 3 countries N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SUL…
• MTR² Ended
  2022-502790-42-00 Phase II 1 country
• Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended
  2022-500571-32-00 Phase II 1 country TISLELIZUMAB
• Pembro-CORE pilot Ended
  2022-501306-35-00 Phase II 1 country PEMBROLIZUMAB
• Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-D… Ended
  2024-517761-17-00 Phase II 1 country DARATUMUMAB
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended
  2022-500439-35-00 Phase III 11 countries IBRUTINIB; OBINUTUZUMAB; VENETOCLAX
• Evaluation of a treatment with bendamustine, followed by obinutuzumab, zanubrutinib and venetoclax in patients with relapsed chronic lymphoc… Ended
  2022-502201-16-00 Phase II 1 country OBINUTUZUMAB; VENETOCLAX; ZANUBRUTINIB
• Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irin… Halted
  2024-512951-18-00 Phase II 1 country IRINOTECAN
• Prospective pilot trial to address the feasibility and safety of treatment with oral Zinc in GNAO1 associated disorders (ZINCGNAO1) Ended
  2024-512735-72-00 Phase II 1 country ZINC ACETATE DIHYDRATE
• CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients Ended
  2023-507002-14-00 Phase II 2 countries ACALABRUTINIB
• HD21 Ended
  2024-518022-33-00 Phase III 6 countries BRENTUXIMAB VEDOTIN

Showing 1–22 of 22 trials